Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
Novo Nordisk has announced that its obesity drug Saxenda (liraglutide) has been shown to be safe and effective in treating obesity in children aged 6-12 years, based on results from a Phase IIIa trial. 12 September 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
Pharmaceutical
Innovent Biologics has announced positive results from a Phase III trial for mazdutide, a dual agonist targeting GLP-1 and glucagon receptor. 12 September 2024
Pharmaceutical
Novo Nordisk has announced that its obesity drug Saxenda (liraglutide) has been shown to be safe and effective in treating obesity in children aged 6-12 years, based on results from a Phase IIIa trial. 12 September 2024
Pharmaceutical
Lexicon Pharmaceuticals has released new data from a Phase III trial showing that its drug sotagliflozin improves certain glucose control parameters in people with type 2 diabetes. 12 September 2024
Biotechnology
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Pharmaceutical
Shares in Novo Nordisk frequently jump upwards when the latest data on the company’s blockbuster obesity drug Wegovy (semaglutide) are released. 11 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
Terns Pharmaceuticals, a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering. 11 September 2024
Biotechnology
Atara Biotherapeutics has appointed Cokey Nguyen as its new president and chief executive. 11 September 2024
Pharmaceutical
Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes. 11 September 2024
Latest In Brief for Novo Nordisk
Pharmaceutical
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
Latest Related Ones To Watch News
Psyence Biomedical has announced plans to acquire Clairvoyant Therapeutics, a Canadian developer of psilocybin-based treatments. 9 September 2024
5 September 2024
15 July 2024
8 July 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze